Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-ce… Read more
Nurix Therapeutics Inc (NRIX) - Net Assets
Latest net assets as of August 2025: $372.25 Million USD
Based on the latest financial reports, Nurix Therapeutics Inc (NRIX) has net assets worth $372.25 Million USD as of August 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($522.47 Million) and total liabilities ($150.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $372.25 Million |
| % of Total Assets | 71.25% |
| Annual Growth Rate | 89.56% |
| 5-Year Change | 81.55% |
| 10-Year Change | N/A |
| Growth Volatility | 110.88 |
Nurix Therapeutics Inc - Net Assets Trend (2018–2024)
This chart illustrates how Nurix Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nurix Therapeutics Inc (2018–2024)
The table below shows the annual net assets of Nurix Therapeutics Inc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-11-30 | $526.99 Million | +162.85% |
| 2023-11-30 | $200.49 Million | -33.98% |
| 2022-11-30 | $303.70 Million | -11.28% |
| 2021-11-30 | $342.30 Million | +17.93% |
| 2020-11-30 | $290.27 Million | +3149.36% |
| 2019-11-30 | $-9.52 Million | -183.88% |
| 2018-11-30 | $11.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nurix Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 70001200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (November 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $76.00K | 0.01% |
| Other Comprehensive Income | $150.00K | 0.03% |
| Other Components | $1.27 Billion | 240.14% |
| Total Equity | $526.99 Million | 100.00% |
Nurix Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Nurix Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
S.ENER.ELEC.SP.GDR REGS 1
F:ECEA
|
$1.11 Billion |
|
Fangda Special Steel Technology Co Ltd
SHG:600507
|
$1.11 Billion |
|
Israel Corporation Ltd
OTCGREY:IRLCF
|
$1.11 Billion |
|
Anhui Tongguan Copper Foil Group Co. Ltd.
SHE:301217
|
$1.11 Billion |
|
Herman Miller Inc
F:MHR
|
$1.11 Billion |
|
Xinjiang Tianfu Energy Co Ltd
SHG:600509
|
$1.11 Billion |
|
Ichor Holdings Ltd
NASDAQ:ICHR
|
$1.11 Billion |
|
Shuangliang Eco-Energy Systems Co Ltd
SHG:600481
|
$1.11 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nurix Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 200,493,000 to 526,993,000, a change of 326,500,000 (162.8%).
- Net loss of 193,569,000 reduced equity.
- New share issuances of 478,495,000 increased equity.
- Other comprehensive income increased equity by 805,000.
- Other factors increased equity by 40,769,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-193.57 Million | -36.73% |
| Share Issuances | $478.50 Million | +90.8% |
| Other Comprehensive Income | $805.00K | +0.15% |
| Other Changes | $40.77 Million | +7.74% |
| Total Change | $- | 162.85% |
Book Value vs Market Value Analysis
This analysis compares Nurix Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.97x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-11-30 | $-2.29 | $15.48 | x |
| 2019-11-30 | $-1.49 | $15.48 | x |
| 2020-11-30 | $18.52 | $15.48 | x |
| 2021-11-30 | $7.98 | $15.48 | x |
| 2022-11-30 | $6.25 | $15.48 | x |
| 2023-11-30 | $3.69 | $15.48 | x |
| 2024-11-30 | $7.85 | $15.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nurix Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -36.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -354.85%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.27x
- Recent ROE (-36.73%) is below the historical average (-30.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -25.18% | 0.82x | 0.00x | $-5.74 Million |
| 2019 | 0.00% | -69.74% | 0.71x | 0.00x | $-15.93 Million |
| 2020 | -14.90% | -242.66% | 0.04x | 1.37x | $-72.27 Million |
| 2021 | -34.24% | -393.93% | 0.06x | 1.39x | $-151.42 Million |
| 2022 | -54.67% | -429.87% | 0.09x | 1.37x | $-196.41 Million |
| 2023 | -71.80% | -186.98% | 0.22x | 1.77x | $-164.00 Million |
| 2024 | -36.73% | -354.85% | 0.08x | 1.27x | $-246.27 Million |
Industry Comparison
This section compares Nurix Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nurix Therapeutics Inc (NRIX) | $372.25 Million | 0.00% | 0.40x | $1.11 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |